Clinical Trial Update: CT-2106 for the Second Line Treatment of Ovarian Cancer [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating CT-2106 as second-line therapy for ovarian cancer. It notes CTI BioPharma as the spo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CT-2106

Snippet

Sponsor: CTI BioPharma | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED